These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. A matched cohort study of convalescent plasma therapy for COVID-19. Sostin OV; Rajapakse P; Cruser B; Wakefield D; Cruser D; Petrini J J Clin Apher; 2021 Aug; 36(4):523-532. PubMed ID: 33616257 [TBL] [Abstract][Full Text] [Related]
48. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection. Baldeón ME; Maldonado A; Ochoa-Andrade M; Largo C; Pesantez M; Herdoiza M; Granja G; Bonifaz M; Espejo H; Mora F; Abril-López P; Armijo LKR; Pacheco V; Salazar R; Reinthaller S; Zertuche F; Fornasini M Transfus Med; 2022 Apr; 32(2):153-161. PubMed ID: 35001439 [TBL] [Abstract][Full Text] [Related]
49. In patients hospitalized with COVID-19, adding convalescent plasma to usual care did not reduce 28-d mortality. Dionne JC; Oczkowski SJW Ann Intern Med; 2021 Oct; 174(10):JC113. PubMed ID: 34606320 [TBL] [Abstract][Full Text] [Related]
50. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial. Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B PLoS Med; 2021 Mar; 18(3):e1003415. PubMed ID: 33657114 [TBL] [Abstract][Full Text] [Related]
51. Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Wooding DJ; Bach H Clin Microbiol Infect; 2020 Oct; 26(10):1436-1446. PubMed ID: 32791241 [TBL] [Abstract][Full Text] [Related]
52. Outcome of SARS CoV-2 inpatients treated with convalescent plasma: One-year of data from the Veneto region (Italy) Registry. De Silvestro G; Marson P; La Raja M; Cattelan AM; Guarnieri G; Monticelli J; Tiberio I; Vianello A; Gandini G; Gessoni G; Fiorin F; Sardella C; Astolfi L; Saia M; Eur J Intern Med; 2022 Mar; 97():42-49. PubMed ID: 34980505 [TBL] [Abstract][Full Text] [Related]
53. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients. Greenbaum U; Klein K; Martinez F; Song J; Thall PF; Ramdial JL; Knape C; Aung FM; Scroggins J; Knopfelmacher A; Mulanovich V; Borjan J; Adachi J; Muthu M; Leung C; Medina MC; Champlin R; Olson A; Alousi A; Rezvani K; Shpall EJ Front Immunol; 2021; 12():675679. PubMed ID: 33995420 [TBL] [Abstract][Full Text] [Related]
54. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19. Ray Y; Paul SR; Bandopadhyay P; D'Rozario R; Sarif J; Raychaudhuri D; Bhowmik D; Lahiri A; Vasudevan JS; Maurya R; Kanakan A; Sharma S; Kumar M; Singh P; Roy R; Chaudhury K; Maiti R; Bagchi S; Maiti A; Perwez MM; Mondal A; Tewari A; Mandal S; Roy A; Saha M; Biswas D; Maiti C; Bhaduri R; Chakraborty S; Sarkar BS; Haldar A; Saha B; Sengupta S; Pandey R; Chatterjee S; Bhattacharya P; Paul S; Ganguly D Nat Commun; 2022 Jan; 13(1):383. PubMed ID: 35046397 [TBL] [Abstract][Full Text] [Related]
55. Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden. Dillner J; Ursing J BMJ Open; 2021 Dec; 11(12):e048337. PubMed ID: 34880010 [TBL] [Abstract][Full Text] [Related]
56. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma. Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160 [TBL] [Abstract][Full Text] [Related]
57. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. Avendaño-Solá C; Ramos-Martínez A; Muñez-Rubio E; Ruiz-Antorán B; Malo de Molina R; Torres F; Fernández-Cruz A; Calderón-Parra J; Payares-Herrera C; Díaz de Santiago A; Romera-Martínez I; Pintos I; Lora-Tamayo J; Mancheño-Losa M; Paciello ML; Martínez-González AL; Vidán-Estévez J; Nuñez-Orantos MJ; Saez-Serrano MI; Porras-Leal ML; Jarilla-Fernández MC; Villares P; de Oteyza JP; Ramos-Garrido A; Blanco L; Madrigal-Sánchez ME; Rubio-Batllés M; Velasco-Iglesias A; Paño-Pardo JR; Moreno-Chulilla JA; Muñiz-Díaz E; Casas-Flecha I; Pérez-Olmeda M; García-Pérez J; Alcamí J; Bueno JL; Duarte RF; J Clin Invest; 2021 Oct; 131(20):. PubMed ID: 34473652 [TBL] [Abstract][Full Text] [Related]
58. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial. Nickols NG; Mi Z; DeMatt E; Biswas K; Clise CE; Huggins JT; Maraka S; Ambrogini E; Mirsaeidi MS; Levin ER; Becker DJ; Makarov DV; Adorno Febles V; Belligund PM; Al-Ajam M; Muthiah MP; Montgomery RB; Robinson KW; Wong YN; Bedimo RJ; Villareal RC; Aguayo SM; Schoen MW; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Orshansky G; Norman LE; Tran S; Ghayouri L; Tsai S; Geelhoed M; Rettig MB JAMA Netw Open; 2022 Apr; 5(4):e227852. PubMed ID: 35438754 [TBL] [Abstract][Full Text] [Related]
59. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
60. Convalescent plasma for covid19 - How long should a donor be excluded from donation? Kutner JM; Bonet-Bub C; Yokoyama APH; Sakashita AM; Pinho JRR; Hamerschlak N; Rizzo LV Transfus Apher Sci; 2020 Oct; 59(5):102873. PubMed ID: 32713627 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]